Insider trade

CEO exercised or converted 29K REGN derivative securities

Traded Dec 31, 2025 · Filed Jan 5, 2026

Regeneron PharmaceuticalsREGN

29K
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 31, 2025
Reporting period: Not applicable
Filed with the SEC: Jan 5, 2026

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001218629-26-000002

Filed / recorded

Jan 5, 2026, 10:53 PM UTC

Added to OQRO

Oct 2, 2026, 12:28 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

REGENERON PHARMACEUTICALS, INC.

Issuer CIK

872589

Ticker

REGN

Reporting person

Leonard S Schleifer

Relationship

Director, Officer

Officer title

Bd. Co-Chair, President & CEO

Security

2020 Performance Stock Units

Table

Derivative (Table II)

Transaction date

Dec 31, 2025

Transaction code

M

Shares / units

28,570

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

595,077

Ownership form

Direct

Amendment

No

Footnotes from the filing

Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.